Skip to main
CMPS

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is focused on addressing treatment-resistant depression (TRD) through its innovative psilocybin therapy, COMP360, which has shown significant efficacy in clinical trials with strong data supporting long-lasting improvements in patient outcomes. The company's recent Phase III clinical trials indicate a durable response in patients, with notable improvements in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores and evidence that redosing enhances therapeutic benefits. Enhanced familiarity with regulatory pathways for psychedelics and increasing patient demand position Compass Pathways favorably for potential FDA approval and successful commercialization, suggesting significant upside potential for the company's stock in the future.

Bears say

Compass Pathways PLC faces significant risks that could adversely affect its stock performance, particularly concerning its COMP360 psilocybin therapy and other pipeline programs. Key concerns include the failure of COMP360 to demonstrate clinically meaningful benefits in upcoming Phase III trials, potential safety signals, and challenges in commercializing the product, all of which could see the stock decline sharply. Additionally, the company's non-revenue-generating status, combined with broader investor caution regarding the psychedelic space and commercialization uncertainties, further contributes to a negative outlook for the stock.

COMPASS Pathways (CMPS) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 7 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.